NeoGenomics, Inc. - Common Stock (NEO)
17.18
-0.81 (-4.50%)
NASDAQ · Last Trade: Oct 29th, 11:37 AM EDT
News & Press Releases
What NeoGenomics (NEO) Said on Its Q3 Earnings Callmarketbeat.com
NeoGenomics (NASDAQ:NEO) reported third-quarter revenue growth of 11% year over year, led by continued expansion in next-generation sequencing, or NGS, testing, while raising its full-year revenue and adjusted EBITDA guidance.
Total third-quarter revenue reached $209 million, above the company’s ex
Via MarketBeat · October 29, 2026
NeoGenomics (NEO) Q3 2026 Earnings Call Transcriptfool.com
NGS revenue surged 29% as management raised full-year guidance.
Via The Motley Fool · October 29, 2026
NeoGenomics (NASDAQ:NEO) Posts In-Line Q3 Revenue and Above-Consensus EPSchartmill.com
Via Chartmill · October 28, 2026
NeoGenomics’s (NASDAQ:NEO) Q3 2026 sales beat estimates
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 11.4% yea...
Via StockStory · October 28, 2026
NeoGenomics Reports Third Quarter 2026 Results
NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third-quarter results for the period ended September 30, 2026.
By NeoGenomics, Inc. · Via Business Wire · October 28, 2026
Earnings to watch: NeoGenomics (NEO) reports Q3 results tomorrow
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting earnings this Wednesday after market close. Here’s what investors should kno...
Via StockStory · October 26, 2026
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
NeoGenomics, Inc. (NASDAQ: NEO), a provider of oncology diagnostic solutions that enable precision medicine across the cancer care continuum, has expanded its partnership with Indica Labs, a global leader in AI-powered digital pathology. The collaboration is intended to scale NeoGenomics' digital pathology infrastructure and accelerate AI-driven diagnostics across its enterprise, giving healthcare providers and their patients more timely, consistent access to advanced diagnostic insight.
By NeoGenomics, Inc. · Via Business Wire · October 15, 2026
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights.
By NeoGenomics, Inc. · Via Business Wire · October 14, 2026
3 Small-Cap Stocks with Questionable Fundamentals
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Via StockStory · October 13, 2026
Why NeoGenomics (NEO) Stock Is Up Today
What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 3.6% in the pre-market session after the company announced an ...
Via StockStory · October 6, 2026
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that as part of a planned succession, its Board of Directors has appointed Warren Stone, current President and Chief Operating Officer (COO), as Chief Executive Officer (CEO) and a member of the Board, effective January 4, 2027. Tony Zook, the Company’s current CEO and a member of the Board, will assume the role of Executive Chair at that time and will continue to work in close alignment with Mr. Stone and the Board.
By NeoGenomics, Inc. · Via Business Wire · October 5, 2026
3 Healthcare Stocks We’re Skeptical Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
Via StockStory · September 23, 2026
3 Reasons NEO is Risky and 1 Stock to Buy Instead
What a time it’s been for NeoGenomics. In the past six months alone, the company’s stock price has increased by a massive 138%, reaching $19.30 per share. Th...
Via StockStory · September 22, 2026
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conferencemarketbeat.com
NeoGenomics (NASDAQ:NEO) executives outlined the company’s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home.
Speaking at t
Via MarketBeat · September 20, 2026
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
Via StockStory · September 18, 2026
A Look Back at Testing & Diagnostics Services Stocks’ Q2 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at NeoGenomics (NASDAQ:NEO) and ...
Via StockStory · September 10, 2026
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that the Company will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, which is being held Sept. 14–16, 2026, in New York, NY.
By NeoGenomics, Inc. · Via Business Wire · September 1, 2026
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors.
By NeoGenomics, Inc. · Via Business Wire · August 26, 2026
3 Unprofitable Stocks Walking a Fine Line
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
Via StockStory · August 21, 2026
3 Stocks Under $50 with Open Questions
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...
Via StockStory · August 6, 2026
3 Healthcare Stocks with Questionable Fundamentals
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...
Via StockStory · August 3, 2026
Why NeoGenomics (NEO) Stock Is Up Today
What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 15.8% in the afternoon session after the company reported seco...
Via StockStory · July 29, 2026
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Via StockStory · July 29, 2026
NeoGenomics Q2 Earnings Call Highlightsmarketbeat.com
NeoGenomics (NASDAQ:NEO) raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical testing and continued expansion in next-generation sequencing.
Total second-quarter revenue rose 11% ye
Via MarketBeat · July 28, 2026
NeoGenomics’s (NASDAQ:NEO) Q2 CY2026: Beats On Revenue
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.2% year on...
Via StockStory · July 28, 2026